ATP2B2

Across TCGA pan-cancer cohorts, ATP2B2 Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated ATP2B2 data layer compared with 23 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher ATP2B2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ATP2B2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and COAD show a favorable association.

ACC, UCEC, and SKCM are the cancer types where ATP2B2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.061	0.675	<.001	27	view →
UCEC	DFS	Median	All	0.788	0.624	.014	16	view →
SKCM	DFS	Median	III,IV	0.233	0.679	<.001	16	view →
COAD	DFS	Median	III,IV	1.000	0.335	.015	13	view →
PAAD	OS	Median	All	0.011	0.641	<.001	12	view →
LGG	DFS	Median	All	0.153	0.829	<.001	8	view →
CESC	DFS	Median	IV	0.053	0.529	<.001	6	view →
OV	DFS	Median	III,IV	0.501	0.155	<.001	6	view →
LUAD	DFS	Median	II,III,IV	0.442	0.693	.016	4	view →
GBM	OS	Median	All	0.075	0.416	.011	3	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

ATP2B2–ACC (DFS)

Open the ACC breakdown →